Table 2.

Primary, secondary, and tertiary outcomes in full analysis set

OutcomesEtelcalcetide GroupMaxacalcitol GroupBetween-Group Difference
T50, min
 0 mo123 (98–174) n=165116 (90–151) n=156
 3 mo141 (117–175) n=149108 (84–145) n=148
 6 mo153 (117–190) n=148105 (79–134) n=141
 12 mo166 (127–218) n=143131 (102–176) n=133
 Change from 0 to 12 mo29 (16 to 43) n=1659 (–4 to 22) n=15620 (7 to 34) P=0.004
Handgrip strength, kg
 0 mo23.5 (17.4–28.4) n=16422.7 (16.4–29.0) n=155
 12 mo22.9 (17.8–28.4) n=14221.6 (16.1–27.8) n=135
 Change from 0 to 12 mo0.0 (–1.0 to 1.1) n=164−0.1 (–1.1 to 0.9) n=1550.2 (–0.9 to 1.2) P=0.76
DASC-21, points
 0 mo22.0 (21.0–23.0) n=16221.0 (21.0–23.0) n=150
 12 mo21.5 (21.0–23.0) n=14021.0 (21.0–23.0) n=133
 Change from 0 to 12 mo−0.0 (–1.0 to 1.0) n=1620.6 (–0.5 to 1.6) n=150−0.6 (–1.6 to 0.5) P=0.29
  • Measurements at each visit were summarized as medians (interquartile ranges) with number of patients. Changes from 0 to 12 months and between-group differences were least square means (95% confidence intervals), which were estimated with imputation of missing data by the last observation carried forward method. T50, serum calcification propensity; 0 mo, visit at baseline; 3 mo, visit at 3 months; 6 mo, visit at 6 months; 12 mo, visit at 12 months; DASC-21, Dementia Assessment Sheet for Community-Based Integrated Care System.